Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1625 1629 4125
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17799597 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | Non-Final OA | The Regents of the University of California |
| 18422541 | METHODS OF TREATING FIBROTIC PATHOLOGIES | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 19294542 | METHODS OF TREATMENT OF JAK INHIBITION RESPONSIVE CONDITIONS WITH DEUTERATED JAK INHIBITORS | Non-Final OA | Sun Pharmaceutical Industries, Inc. |
| 18402803 | 2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL CONTAINING COMPOUNDS USEFUL AS IMMUNOMODULATORS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18603554 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | Final Rejection | Xenon Pharmaceuticals Inc. |
| 19079373 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | Non-Final OA | INSIGNIA PHARMACEUTICALS, LLC |
| 17963929 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | Non-Final OA | ThermoLife International, LLC |
| 17584116 | COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN AND BREAST CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18065073 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRAN TLEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | Non-Final OA | Florida State University Research Foundation, Inc. |
| 17417625 | COMBINATION THERAPY OF SOLID CANCER | Non-Final OA | MOR RESEARCH APPLICATIONS LTD. |
| 17837224 | COMPOSITIONS AND METHODS FOR INCREASING CELL SURFACE OXYTOCIN RECEPTOR (OXTR) | Non-Final OA | Washington University |
| 18728545 | COMBINATIONS OF VITAMIN D3, NIACINAMIDE AND LIPOIC ACID FOR USE IN THE MAINTENANCE OF HEALTHY BLOOD GLUCOSE LEVELS | Final Rejection | LAY SCIENCES INC. |
| 18042801 | COMPOSITION FOR TREATING CORONAVIRUS DISEASE-19, COMPRISING PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID DERIVATIVES, OPTICAL ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ACTIVE INGREDIENT | Non-Final OA | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION |
| 18009645 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | Non-Final OA | The Children's Medical Center Corporation |
| 17271045 | METHODS FOR REDUCING THE RISK OF DIABETES IN PATIENTS BEING TREATED FOR HIGH CHOLESTEROL-RELATED ILLNESSES | Non-Final OA | Esperion Therapeutics, Inc. |
| 17294829 | COMPOSITION FOR STABILIZING POORLY SOLUBLE INGREDIENTS AND COSMETIC COMPOSITION COMPRISING SAME | Non-Final OA | LG HOUSEHOLD & HEALTH CARE LTD. |
| 18692114 | SMALL MOLECULE COMPOUNDS HAVING NAPHTHYLAMINE STRUCTURE AND APPLICATION THEREOF | Non-Final OA | Hangzhou PhecdaMed Co., Ltd. |
| 17574781 | METHOD FOR IDENTIFYING TREATMENT OF INFECTIONS CAUSED BY PATHOGENS OF DIVERSE ORIGIN | Final Rejection | SystaMedic Inc. |
| 18501729 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | Non-Final OA | IDEAYA BIOSCIENCES, INC. |
| 17765354 | DRUG FOR TREATING ARTERY-RELATED DISEASES, AND USE THEREOF | Non-Final OA | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES |
| 17429732 | PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND | Non-Final OA | HK INNO.N CORPORATION |
| 18138545 | COMBINATION THERAPY WITH MEK INHIBITOR AND CDK4/6 INHIBITOR TO TREAT PANCREATIC CANCER | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 18023600 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Non-Final OA | Accencio LLC |
| 18010045 | MARC1 INHIBITORS FOR TREATMENT OF LIPID METABOLISM DISORDERS | Non-Final OA | CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL |
| 17701349 | PARAXANTHINE-BASED COMPOSITIONS FOR PROMOTING WEIGHT LOSS | Final Rejection | Ingenious Ingredients, LP |
| 17989981 | PHARMACEUTICAL COMPOSITIONS COMPRISING DICARBOXYLIC ACIDS AND THEIR THERAPEUTIC APPLICATIONS | Final Rejection | Cura Therapeutics, LLC |
| 17920731 | APPLICATION OF COMPOUNDS IN CONTROLLING OR KILLING MITES | Non-Final OA | GUANGZHOU MEDICAL UNIVERSITY PROPERTY OPERATION LIMITED CORPORATION |
| 17764193 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS AND USE THEREOF | Non-Final OA | Prime Reach Trading Limited |
| 17417712 | TREATMENT USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND | Non-Final OA | SHOYAO HOLDINGS (BEIJING) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy